Medications for Mantle Cell Lymphoma

16 results

  • Bortezomib (bortezomib)

    (Bortezomib)
    Novadoz Pharmaceuticals LLC
    Usage: Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.

  • Bortezomib (bortezomib)

    (Bortezomib)
    Accord Healthcare Inc.
    Usage: Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.

  • Bortezomib (bortezomib)

    (BORTEZOMIB)
    Hospira, Inc.
    Usage: Bortezomib for Injection is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.

  • Bortezomib (bortezomib)

    (bortezomib)
    Hikma Pharmaceuticals USA Inc.
    Usage: Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.

  • Bortezomib (bortezomib)

    (Bortezomib)
    NorthStar RxLLC
    Usage: Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.

  • Boruzu (bortezomib)

    (Bortezomib)
    Amneal Pharmaceuticals LLC
    Usage: BORUZU is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.

  • Breyanzi

    (Lisocabtagene maraleucel)
    Juno Therapeutics, Inc.
    Usage: BREYANZI is indicated for adult patients with large B-cell lymphoma (LBCL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), follicular lymphoma (FL), or mantle cell lymphoma (MCL) who are relapsed or refractory after multiple lines of therapy, with specific prior treatment conditions for CLL and MCL.

  • Calquence

    (Acalabrutinib)
    AstraZeneca Pharmaceuticals LP
    Usage: CALQUENCE is indicated for adult patients with previously untreated mantle cell lymphoma (MCL) ineligible for autologous stem cell transplantation, previously treated MCL, and for those with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

  • Calquence

    (acalabrutinib)
    AstraZeneca Pharmaceuticals LP
    Usage: CALQUENCE is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous stem cell transplantation, previously treated MCL patients, and those with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

  • Jaypirca

    (pirtobrutinib)
    Eli Lilly and Company
    Usage: JAYPIRCA® is indicated for adult patients with relapsed or refractory mantle cell lymphoma (MCL) after two systemic therapies, including a BTK inhibitor, and for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after two prior therapies, including a BTK and BCL-2 inhibitor.